Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by Mizuho in a research note issued to investors on Friday. They currently have a $27.00 target price on the stock. Mizuho’s price target indicates a potential upside of 50.92% from the stock’s previous close.
TEVA has been the topic of a number of other reports. Jefferies Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, March 20th. They set a “hold” rating and a $19.00 price objective on the stock. Zacks Investment Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Friday, January 12th. Royal Bank of Canada upgraded shares of Teva Pharmaceutical Industries from an “underperform” rating to a “sector perform” rating and set a $18.00 price objective on the stock in a report on Friday, February 9th. Vetr upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating and set a $23.57 price objective on the stock in a report on Tuesday, January 30th. Finally, Citigroup upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Thursday, January 4th. Eleven analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $19.82.
Shares of NYSE:TEVA traded up $0.18 during midday trading on Friday, reaching $17.89. 3,032,284 shares of the company were exchanged, compared to its average volume of 14,623,679. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $33.82. The company has a quick ratio of 0.58, a current ratio of 0.86 and a debt-to-equity ratio of 1.91. The firm has a market cap of $18,222.44, a price-to-earnings ratio of 4.55, a PEG ratio of 1.56 and a beta of 0.67.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the business posted $1.38 earnings per share. The firm’s quarterly revenue was down 15.9% on a year-over-year basis. research analysts expect that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current fiscal year.
In other news, EVP Mark Sabag sold 5,050 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $19.68, for a total value of $99,384.00. Following the completion of the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 10,734 shares of company stock valued at $204,795. Insiders own 7.10% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in TEVA. Franklin Resources Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 8.2% during the 4th quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock worth $1,506,309,000 after buying an additional 6,009,897 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $118,487,000. OppenheimerFunds Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $69,418,000. Swiss National Bank boosted its holdings in shares of Teva Pharmaceutical Industries by 0.9% during the 4th quarter. Swiss National Bank now owns 3,523,499 shares of the company’s stock worth $66,770,000 after buying an additional 32,000 shares during the period. Finally, Teachers Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 66.5% during the 4th quarter. Teachers Advisors LLC now owns 3,221,405 shares of the company’s stock worth $61,046,000 after buying an additional 1,286,637 shares during the period. 58.22% of the stock is owned by institutional investors.
WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/20/teva-pharmaceutical-industries-teva-buy-rating-reaffirmed-at-mizuho.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.